This week, a travoprost intracameral implant shows encouraging phase 1 results, the ILM could play a key role in repairing damaged retinas and acupuncture treatment leaves a patient seeing lights.

This week, Glaukos reports positive results from 2 glaucoma trials, CorNeat Vision’s artificial cornea is implanted into its first trial participant and Notal Vision tests out their at-home OCT platform for monitoring AMD.

This retrospective, interventional case series evaluated the long-term safety and efficacy of accelerated transepithelial CXL in pediatric eyes with progressive keratoconus.

This single-center retrospective study analyzes consultations managed by an ophthalmic hospitalist covering a children's hospital.

From a new approach to phaco chop to slit-lamp examinations during a pandemic, here’s a look at the year’s most-viewed 1-Minute Videos and surgical videos.

This analysis characterizes posterior corneal surface features in patients with Down syndrome.

This week, a new study finds SARS-CoV-2 in donor corneal tissues, first-in-class treatments for glaucoma and dry eye show promise and researchers discover rosette-shaped deposits on the surface of an IOL.

Investigators evaluated changes in ocular biometrics among children receiving 0.05%, 0.025% and 0.01% atropine in the LAMP study.

Using a national sample of U.S. patients, this study is the first to estimate the effect of obstructive sleep apnea on the absolute risk of central serous chorioretinopathy (CSC).

The authors evaluated the outcomes of bilateral toric extended depth-of-focus intraocular lens (EDOF IOL) implantation targeted for micromonovision.

The authors of this case series detail ocular abnormalities in 2 patients with COVID-19 after prolonged prone positioning.

This retrospective study measured recurrence of inflammation after switching from original infliximab (Remicade) to a biosimilar for noninfectious uveitis.

This study assessed OCT angiography-derived vessel metrics of the macula and optic nerve head that may predict progression of diabetic retinopathy.

This retrospective study assessed variables associated with patients’ self-assessed postoperative pain after photorefractive keratectomy (PRK).

Investigators assessed whether soft multifocal contact lenses with a high add power could slow pediatric myopia progression.

This week, research hints that the cornea may have resistance against SARS-CoV-2, Novartis invests in a novel optogenetic gene therapy technology, and Bausch + Lomb launches a preloaded toric IOL.

This study evaluates the impact of rapid high-dose intravenous methylprednisolone pulse therapy in patients with serum anti-aquaporin-4 immunoglobulin G (AQP4-IgG)–positive neuromyelitis optica spectrum disorders (NMOSDs) who had an attack of optic neuritis.

This week, clinicians report another possible ocular manifestation of COVID-19, the FDA approves new drugs for dry eye and pediatric vernal keratoconjunctivitis, and researchers propose a new mechanism to treat retinal diseases.

This retrospective analysis aimed to quantitatively characterize aggressive posterior retinopathy of prematurity in a large cohort.

This week, the second-generation Kahook Dual Blade is set to hit U.S. markets, pegcetacoplan appears to slow geographic atrophy and a new light-sensing protein offers hope for people with degenerative retinal diseases.

Jeffrey Goldberg, MD, PhD, Blumenkranz Smead professor and chair of ophthalmology at Stanford University, has been elected to the National Academy of Medicine.

This study identified risk factors for patients who are lost to follow-up while undergoing treatment for proliferative diabetic retinopathy (PDR).

This study attempted to identify the amount and time course of corneal haze development after transepithelial corneal collagen crosslinking (CXL) in patients with keratoconus.

This phase 2 trial assessed extended dosing of faricimab compared with monthly ranibizumab for neovascular AMD.

This week, the FDA awards orphan drug designation to a nonviral gene therapy for retinitis pigmentosa, a novel eye drop for Demodex blepharitis shines in phase 2 trials and an eyelash embedded in the retina causes ocular inflammation.